Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy.
Wiendl H, Schmierer K, Hodgkinson S, Derfuss T, Chan A, Sellebjerg F, Achiron A, Montalban X, Prat A, De Stefano N, Barkhof F, Leocani L, Vermersch P, Chudecka A, Mwape C, Holmberg KH, Boschert U, Roy S; MAGNIFY-MS Study Group. Wiendl H, et al. Among authors: derfuss t. Neurol Neuroimmunol Neuroinflamm. 2022 Nov 21;10(1):e200048. doi: 10.1212/NXI.0000000000200048. Print 2023 Jan. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 36411081 Free PMC article.
T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
Ricklin ME, Lorscheider J, Waschbisch A, Paroz C, Mehta SK, Pierson DL, Kuhle J, Fischer-Barnicol B, Sprenger T, Lindberg RL, Kappos L, Derfuss T. Ricklin ME, et al. Among authors: derfuss t. Neurology. 2013 Jul 9;81(2):174-81. doi: 10.1212/WNL.0b013e31829a3311. Epub 2013 May 22. Neurology. 2013. PMID: 23700335
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.
Kappos L, Radue EW, Comi G, Montalban X, Butzkueven H, Wiendl H, Giovannoni G, Hartung HP, Derfuss T, Naegelin Y, Sprenger T, Mueller-Lenke N, Griffiths S, von Rosenstiel P, Gottschalk R, Zhang Y, Dahlke F, Tomic D; TOFINGO study group. Kappos L, et al. Among authors: derfuss t. Neurology. 2015 Jul 7;85(1):29-39. doi: 10.1212/WNL.0000000000001706. Epub 2015 May 29. Neurology. 2015. PMID: 26024899 Free PMC article.
Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS.
Zimmermann M, Sanderson NS, Rasenack M, Lalive PH, Lang AB, Curtin F, Lindberg RL, Kappos L, Derfuss T. Zimmermann M, et al. Among authors: derfuss t. Neurol Neuroimmunol Neuroinflamm. 2015 Aug 20;2(5):e144. doi: 10.1212/NXI.0000000000000144. eCollection 2015 Oct. Neurol Neuroimmunol Neuroinflamm. 2015. PMID: 26380353 Free PMC article.
Optimizing treatment success in multiple sclerosis.
Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, Vollmer T, Schippling S. Ziemssen T, et al. Among authors: derfuss t. J Neurol. 2016 Jun;263(6):1053-65. doi: 10.1007/s00415-015-7986-y. Epub 2015 Dec 24. J Neurol. 2016. PMID: 26705122 Free PMC article. Review.
Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development.
Meira M, Sievers C, Hoffmann F, Haghikia A, Rasenack M, Décard BF, Kuhle J, Derfuss T, Kappos L, Lindberg RL. Meira M, et al. Among authors: derfuss t. Neurol Neuroimmunol Neuroinflamm. 2016 Mar 31;3(3):e223. doi: 10.1212/NXI.0000000000000223. eCollection 2016 Jun. Neurol Neuroimmunol Neuroinflamm. 2016. PMID: 27088119 Free PMC article.
ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.
Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F. Montalban X, et al. Among authors: derfuss t. Eur J Neurol. 2018 Feb;25(2):215-237. doi: 10.1111/ene.13536. Epub 2018 Jan 19. Eur J Neurol. 2018. PMID: 29352526 Free article.
188 results